Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Page 1
Association of Baseline Luminal Narrowing With Ileal Microbial Shifts and Gene Expression Programs and Subsequent Transmural Healing in Pediatric Crohn Disease.
Inflamm Bowel Dis. 2021 Oct 20;27(11):1707-1718. doi: 10.1093/ibd/izaa339.
Inflamm Bowel Dis. 2021.
PMID: 33452801
Free PMC article.
BACKGROUND: Transmural healing (TH) is associated with better long-term outcomes in Crohn disease (CD), whereas pretreatment ileal gene signatures encoding myeloid inflammatory responses and extracellular matrix production are associated with stricturing. ...
BACKGROUND: Transmural healing (TH) is associated with better long-term outcomes in Crohn disease (CD), whereas pretreatment ileal ge …
Cumulative Influence of Inflammatory Response Genetic Variation on Long-Term Neurobehavioral Outcomes after Pediatric Traumatic Brain Injury Relative to Orthopedic Injury: An Exploratory Polygenic Risk Score.
Treble-Barna A, Pilipenko V, Wade SL, Jegga AG, Yeates KO, Taylor HG, Martin LJ, Kurowski BG.
Treble-Barna A, et al. Among authors: jegga ag.
J Neurotrauma. 2020 Jul 1;37(13):1491-1503. doi: 10.1089/neu.2019.6866. Epub 2020 Mar 11.
J Neurotrauma. 2020.
PMID: 32024452
Free PMC article.
The present study examined the cumulative influence of candidate genes involved in the inflammatory response on long-term neurobehavioral recovery in children with early childhood TBI relative to children with orthopedic injuries (OI). ...Linear regression models tested th …
The present study examined the cumulative influence of candidate genes involved in the inflammatory response on long-term neurobehavi …
Item in Clipboard
Genetic Influences on Behavioral Outcomes After Childhood TBI: A Novel Systems Biology-Informed Approach.
Kurowski BG, Treble-Barna A, Pilipenko V, Wade SL, Yeates KO, Taylor HG, Martin LJ, Jegga AG.
Kurowski BG, et al. Among authors: jegga ag.
Front Genet. 2019 May 22;10:481. doi: 10.3389/fgene.2019.00481. eCollection 2019.
Front Genet. 2019.
PMID: 31191606
Free PMC article.
Design: Cross-sectional evaluation of the association of genetic factors with early (~ 6 months) and long-term (~ 7 years) post-TBI behavioral outcomes. We combined systems biology and genetic association testing methodologies to identify biologic pathways associated with …
Design: Cross-sectional evaluation of the association of genetic factors with early (~ 6 months) and long-term (~ 7 years) post-TBI b …
Item in Clipboard
Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy.
Kasam RK, Reddy GB, Jegga AG, Madala SK.
Kasam RK, et al. Among authors: jegga ag.
Front Pharmacol. 2019 May 17;10:532. doi: 10.3389/fphar.2019.00532. eCollection 2019.
Front Pharmacol. 2019.
PMID: 31156440
Free PMC article.
TGFalpha mice treated with nintedanib show increased active caspase 3-positive cells in fibrotic lesions and reduced fibroproliferation and collagen production. Further, the long-term nintedanib therapy attenuated fibrocyte accumulation, collagen deposition, and lung funct …
TGFalpha mice treated with nintedanib show increased active caspase 3-positive cells in fibrotic lesions and reduced fibroproliferation and …
Item in Clipboard
Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.
Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, Broyl A, van Duin M, Sonneveld P, Cottini F, Anderson KC, Driscoll JJ.
Malek E, et al. Among authors: jegga ag.
Leukemia. 2017 Mar;31(3):645-653. doi: 10.1038/leu.2016.258. Epub 2016 Sep 28.
Leukemia. 2017.
PMID: 27677741
Free PMC article.
While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limiting toxicities and drug resistance limit the long-term utility. The E3 ubiquitin ligase Skp1-Cullin-1-Skp2 (SCF(Skp2)) promotes prote …
While clinical benefit of the proteasome inhibitor (PI) bortezomib (BTZ) for multiple myeloma (MM) patients remains unchallenged, dose-limit …
Item in Clipboard
Cite
Cite